Repligen (NASDAQ:RGEN) Releases FY 2025 Earnings Guidance

Key Points

• Repligen has provided FY 2025 earnings guidance with expected EPS between 1.650 and 1.720, slightly above the consensus estimate of 1.681, and revenue guidance of $715-$735 million, surpassing the consensus estimate of $709.4 million.
• The company's stock has decreased by 1.7% and currently trades at $119.65, with a market capitalization of $6.72 billion and a P/E ratio of -265.89.
• Recent analyst ratings indicate a mixed outlook, with some analysts issuing "buy" ratings while others have downgraded their expectations; the consensus rating remains a "Moderate Buy" with an average target price of $169.92.

Repligen (NASDAQ:RGEN - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 1.650-1.720 for the period, compared to the consensus EPS estimate of 1.681. The company issued revenue guidance of $715.0 million-$735.0 million, compared to the consensus revenue estimate of $709.4 million.

Repligen Trading Up 1.6%

Shares of Repligen stock traded up $1.84 during midday trading on Friday, reaching $118.91. 941,488 shares of the company's stock traded hands, compared to its average volume of 783,381. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The company has a market cap of $6.68 billion, a PE ratio of -475.62, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11. The stock has a 50 day moving average of $123.39 and a 200-day moving average of $136.49. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.40 EPS. As a group, equities analysts expect that Repligen will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of research reports. Barclays initiated coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective for the company. Canaccord Genuity Group cut their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Wells Fargo & Company cut their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, JPMorgan Chase & Co. cut their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $169.45.

Hedge Funds Weigh In On Repligen

Institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its holdings in Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock valued at $18,067,000 after buying an additional 20,375 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock worth $814,000 after purchasing an additional 6,238 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Repligen during the 1st quarter valued at $262,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.